InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

On April 28, 2026, InflaRx N.V. announced that it has regained compliance with the Nasdaq Minimum Bid Price Requirement set forth in Nasdaq Listing Rule 5450(a)(1). The company had previously been notified on March 11, 2026, that its ordinary shares had closed below the $1.00 minimum bid price for 30 consecutive business days. To regain compliance, the closing bid price of the company’s ordinary shares was required to be at least $1.00 per share for a minimum of 10 consecutive business days. Nasdaq confirmed that InflaRx met this requirement during the period from April 13, 2026, to April 24, 2026. As a result, the deficiency matter is now closed, and the company's shares will continue to be listed on The Nasdaq Stock Market. No clinical data or regulatory updates were included in this filing.